z-logo
Premium
Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women
Author(s) -
Homeida Mamoun,
Halliwell Michael,
Branch Robert A.
Publication year - 1978
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1978242228
Subject(s) - medicine , discontinuation , microgram , ethinylestradiol , drug , endocrinology , oral administration , drug metabolism , population , physiology , metabolism , pharmacology , research methodology , chemistry , in vitro , environmental health , biochemistry
Liver volume and antipyrine disposition have been investigated in healthy premenopausal women who received 30 µg ethinyl oestradiol + 500 µg dl‐norgesterol as an oral contraceptive. Six months‐ treatment was associated with a 17% increase in liver volume while no change occurred in age‐matched control subjects. In the same subjects the contraceptive decreased antipyrine clearance by 21%. Thus the contraceptive markedly reduced drug‐metabolizing activity per unit volume of liver by 33%. In additional subjects, discontinuation of the contraceptive resulted in a 30% increase in antipyrine clearance. These observations confirm that conventional oral contraceptive therapy to premenopausal women increases hepatic size and that it is a potent inhibitor of drug‐metabolizing activity.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom